임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
30건 표시
- 1상모집 중· Breast NeoplasmsA Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
리드: 노바티스
- 1상모집 중· Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
리드: 노바티스
- 1상모집 중· Breast CancerStudy of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
리드: 노바티스
- 1상모집 중· Advanced HR+/HER2- Breast CancerStudy of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
리드: 노바티스
- 1상모집 중· Metastatic Castration-resistant Prostate Cancer (mCRPC)A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
리드: 노바티스
- 1상모집 중· Advanced Malignancies and Hepatic ImpairmentPharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
리드: 노바티스
- 1상모집 중· Primary Myelofibrosis (PMF)Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
리드: 노바티스
- 1상모집 중· Heart Failure With Reduced Ejection FractionA Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
리드: 노바티스
- 1상모집 중· Metastatic Prostate Cancer177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
협력: 노바티스
- 1상모집 중· Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaAsciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
협력: 노바티스
- 1상모집 중· Pancreatic Ductal AdenocarcinomaPhase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
리드: 노바티스
- 1상모집 중· Chronic Kidney DiseaseSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
리드: 노바티스
- 1상모집 중· Small Cell Lung CarcinomaPhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
리드: 노바티스
- 1상모집 중· Charcot-Marie-Tooth Disease, Type 1AA First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.
리드: 노바티스
- 1상모집 중· Metastatic Castrate Resistant Prostate Cancer (mCRPC)Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
협력: 노바티스
- 1상모집 중· Metastatic Castration-Resistant Prostate CancerA Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
리드: 노바티스
- 1상모집 중· Pancreatic Ductal AdenocarcinomaPhase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
리드: 노바티스
- 1상모집 중· Recurrent Ovarian CancerCPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
협력: 노바티스
- 1상모집 중· Metastatic Breast CancerPhase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
협력: 노바티스, 화이자
- 1상모집 중· Metastatic MelanomaNilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
협력: 노바티스
- 1상모집 중· Metastatic Breast CancerRibociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
협력: 노바티스
- 1상모집 중· Gastroenteropancreatic Neuroendocrine TumorStudy of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
협력: 노바티스
- 1상모집 중· Recurrent World Health Organization (WHO) Grade II GliomaTrametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
협력: 노바티스
- 1상모집 중· B-cell Acute Lymphoblastic LeukemiaABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
협력: 노바티스
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.